Immix Biopharma
Developing BCMA-targeted CAR-T therapy for relapsed or refractory AL amyloidosis.
$13.82
After-hours close−0.10 (−0.72%)
At close$13.92(−2.73%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.18 | — | — |
| Aug 2026 | −$0.17 | −$0.18 | −5.9% |
| May 2026 | −$0.18 | −$0.18 | +0.3% |
| Mar 2026 | −$0.21 | −$0.27 | −28.6% |
| Nov 2025 | −$0.19 | −$0.24 | −26.3% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | −$0.18 | — | — | — | — | — |
| Aug 7, 2026 | −$0.17 | −$0.18 | −5.9% | — | — | — |
| May 7, 2026 | −$0.18 | −$0.18 | +0.3% | — | — | — |
| Mar 25, 2026 | −$0.21 | −$0.27 | −28.6% | — | — | — |
| Nov 7, 2025 | −$0.19 | −$0.24 | −26.3% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 8, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 24, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 29, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 11, 2023 | ||||||
| May 12, 2023 | ||||||
| Mar 27, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 12, 2022 | ||||||
| May 13, 2022 | ||||||
| Mar 28, 2022 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||